Chrysin is a natural flavonoid that has been reported as a potential treatment for non-alcoholic fatty liver disease (NAFLD). Researchers synthesized a novel chrysin derivative prodrug (C-1) and further investigated its potential therapeutic mechanism against NAFLD in vitro and in vivo. C-1 had a low toxicity profile. Their data demonstrated that C-1 may be a promising agent for NAFLD therapy. 

Evaluation experiments of the acute toxicities of C-1 were conducted by Medicilon.

Reference:

Ruiming Zhang, et al. Synthesis and biological evaluation of the novel chrysin prodrug for non-alcoholic fatty liver disease treatment. Front Pharmacol. 2024 Apr 19:15:1336232. doi: 10.3389/fphar.2024.1336232.